Associated Papers
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro.
Bao SS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.
Parikh SJ et al.
Journal of Inorganic Biochemistry, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen.
Yuan LJ et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population.
Wang D et al.
Frontiers in Cardiovascular Medicine, 2022
Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population.
Zhao FL et al.
Frontiers in Pharmacology, 2022
Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison.
Parikh SJ et al.
International Journal of Molecular Sciences, 2021
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease.
Cacabelos R et al.
Pharmaceuticals (basel, Switzerland), 2021
Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals.
Kumondai M et al.
Journal of Personalized Medicine, 2021
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF et al.
Drug Design, Development and Therapy, 2020
Functional Characterization of Pharmcogenetic Variants of Human Cytochrome P450 2C9 in Korean Populations.
Cho MA et al.
Biomolecules & Therapeutics, 2019
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson's Disease.
Cacabelos R et al.
Planta Medica, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy.
Shah M et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2019
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
Impact of CYP2C9 polymorphism found in the Chinese population on the metabolism of propofol in vitro.
Lian QQ et al.
Biological & Pharmaceutical Bulletin, 2015
Effect of CYP2C9 Genetic Polymorphism in a Chinese Population on the Metabolism of Mestranol in vitro.
Hu JH et al.
Pharmacology, 2015
Effects of cytochrome P450 2C9 polymorphism on bosentan metabolism.
Chen M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.
Yin T et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension, 2008
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006